1887

Abstract

Here we describe the design and strength of a new synthetic late-early optimized (LEO) vaccinia virus (VACV) promoter used as a transcriptional regulator of GFP expression during modified vaccinia Ankara infection. In contrast to the described synthetic VACV promoter (pS), LEO induced significantly higher levels of GFP expression within the first hour after infection, which correlated with an enhancement in the GFP-specific CD8 T-cell response detected , demonstrating its potential use in future vaccines.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.057299-0
2013-12-01
2019-10-22
Loading full text...

Full text loading...

/deliver/fulltext/jgv/94/12/2771.html?itemId=/content/journal/jgv/10.1099/vir.0.057299-0&mimeType=html&fmt=ahah

References

  1. Assarsson E. , Greenbaum J. A. , Sundström M. , Schaffer L. , Hammond J. A. , Pasquetto V. , Oseroff C. , Hendrickson R. C. , Lefkowitz E. J. . & other authors ( 2008; ). Kinetic analysis of a complete poxvirus transcriptome reveals an immediate-early class of genes. . Proc Natl Acad Sci U S A 105:, 2140–2145. [CrossRef] [PubMed]
    [Google Scholar]
  2. Baur K. , Brinkmann K. , Schweneker M. , Pätzold J. , Meisinger-Henschel C. , Hermann J. , Steigerwald R. , Chaplin P. , Suter M. , Hausmann J. . ( 2010; ). Immediate-early expression of a recombinant antigen by modified vaccinia virus Ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responses. . J Virol 84:, 8743–8752. [CrossRef] [PubMed]
    [Google Scholar]
  3. Chakrabarti S. , Sisler J. R. , Moss B. . ( 1997; ). Compact, synthetic, vaccinia virus early/late promoter for protein expression. . Biotechniques 23:, 1094–1097.[PubMed]
    [Google Scholar]
  4. Gambotto A. , Dworacki G. , Cicinnati V. , Kenniston T. , Steitz J. , Tüting T. , Robbins P. D. , DeLeo A. B. . ( 2000; ). Immunogenicity of enhanced green fluorescent protein (EGFP) in BALB/c mice: identification of an H2-Kd-restricted CTL epitope. . Gene Ther 7:, 2036–2040. [CrossRef] [PubMed]
    [Google Scholar]
  5. García-Arriaza J. , Nájera J. L. , Gómez C. E. , Sorzano C. O. , Esteban M. . ( 2010; ). Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions. . PLoS ONE 5:, e12395. [CrossRef] [PubMed]
    [Google Scholar]
  6. Gómez C. E. , Nájera J. L. , Jiménez E. P. , Jiménez V. , Wagner R. , Graf M. , Frachette M. J. , Liljeström P. , Pantaleo G. , Esteban M. . ( 2007a; ). Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. . Vaccine 25:, 2863–2885. [CrossRef] [PubMed]
    [Google Scholar]
  7. Gómez C. E. , Nájera J. L. , Jiménez V. , Bieler K. , Wild J. , Kostic L. , Heidari S. , Chen M. , Frachette M. J. . & other authors ( 2007b; ). Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. . Vaccine 25:, 1969–1992. [CrossRef] [PubMed]
    [Google Scholar]
  8. Gómez C. E. , Perdiguero B. , Garcia-Arriaza J. , Esteban M. . ( 2012a; ). Poxvirus vectors as HIV/AIDS vaccines in humans. . Hum Vaccin Immunother 8:, 1192–1207. [CrossRef] [PubMed]
    [Google Scholar]
  9. Gómez C. E. , Perdiguero B. , Jiménez V. , Filali-Mouhim A. , Ghneim K. , Haddad E. K. , Quakkelaar E. D. , Delaloye J. , Harari A. . & other authors ( 2012b; ). Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C. . PLoS ONE 7:, e35485. [CrossRef] [PubMed]
    [Google Scholar]
  10. Good M. F. , Doolan D. L. . ( 2010; ). Malaria vaccine design: immunological considerations. . Immunity 33:, 555–566. [CrossRef] [PubMed]
    [Google Scholar]
  11. Honess R. W. , Roizman B. . ( 1975; ). Regulation of herpesvirus macromolecular synthesis: sequential transition of polypeptide synthesis requires functional viral polypeptides. . Proc Natl Acad Sci U S A 72:, 1276–1280. [CrossRef] [PubMed]
    [Google Scholar]
  12. Kastenmuller W. , Gasteiger G. , Gronau J. H. , Baier R. , Ljapoci R. , Busch D. H. , Drexler I. . ( 2007; ). Cross-competition of CD8+ T cells shapes the immunodominance hierarchy during boost vaccination. . J Exp Med 204:, 2187–2198. [CrossRef] [PubMed]
    [Google Scholar]
  13. Moutaftsi M. , Salek-Ardakani S. , Croft M. , Peters B. , Sidney J. , Grey H. , Sette A. . ( 2009; ). Correlates of protection efficacy induced by vaccinia virus-specific CD8+ T-cell epitopes in the murine intranasal challenge model. . Eur J Immunol 39:, 717–722. [CrossRef] [PubMed]
    [Google Scholar]
  14. Orubu T. , Alharbi N. K. , Lambe T. , Gilbert S. C. , Cottingham M. G. . ( 2012; ). Expression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVA. . PLoS ONE 7:, e40167. [CrossRef] [PubMed]
    [Google Scholar]
  15. Pasquetto V. , Bui H. H. , Giannino R. , Banh C. , Mirza F. , Sidney J. , Oseroff C. , Tscharke D. C. , Irvine K. . & other authors ( 2005; ). HLA-A*0201, HLA-A*1101, and HLA-B*0702 transgenic mice recognize numerous poxvirus determinants from a wide variety of viral gene products. . J Immunol 175:, 5504–5515.[PubMed] [CrossRef]
    [Google Scholar]
  16. Ramírez J. C. , Gherardi M. M. , Esteban M. . ( 2000; ). Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. . J Virol 74:, 923–933. [CrossRef] [PubMed]
    [Google Scholar]
  17. Ross L. , Guarino L. A. . ( 1997; ). Cycloheximide inhibition of delayed early gene expression in baculovirus-infected cells. . Virology 232:, 105–113. [CrossRef] [PubMed]
    [Google Scholar]
  18. Salser W. , Bolle A. , Epstein R. . ( 1970; ). Transcription during bacteriophage T4 development: a demonstration that distinct subclasses of the “early” RNA appear at different times and that some are “turned off” at late times. . J Mol Biol 49:, 271–295. [CrossRef] [PubMed]
    [Google Scholar]
  19. Sánchez-Sampedro L. , Gómez C. E. , Mejías-Pérez E. , Sorzano C. O. S. , Esteban M. . ( 2012; ). High quality long-term CD4+ and CD8+ effector memory populations stimulated by DNA-LACK/MVA-LACK regimen in Leishmania major BALB/c model of infection. . PLoS ONE 7:, e38859. [CrossRef] [PubMed]
    [Google Scholar]
  20. Sette A. , Grey H. , Oseroff C. , Peters B. , Moutaftsi M. , Crotty S. , Assarsson E. , Greenbaum J. , Kim Y. . & other authors ( 2009; ). Definition of epitopes and antigens recognized by vaccinia specific immune responses: their conservation in variola virus sequences, and use as a model system to study complex pathogens. . Vaccine 27: (Suppl 6), G21–G26. [CrossRef] [PubMed]
    [Google Scholar]
  21. Vijayan A. , Gómez C. E. , Espinosa D. A. , Goodman A. G. , Sanchez-Sampedro L. , Sorzano C. O. , Zavala F. , Esteban M. . ( 2012; ). Adjuvant-like effect of vaccinia virus 14K protein: a case study with malaria vaccine based on the circumsporozoite protein. . J Immunol 188:, 6407–6417. [CrossRef] [PubMed]
    [Google Scholar]
  22. Wilson E. H. , Hunter C. A. . ( 2008; ). Immunodominance and recognition of intracellular pathogens. . J Infect Dis 198:, 1579–1581. [CrossRef] [PubMed]
    [Google Scholar]
  23. Yang Z. , Bruno D. P. , Martens C. A. , Porcella S. F. , Moss B. . ( 2010; ). Simultaneous high-resolution analysis of vaccinia virus and host cell transcriptomes by deep RNA sequencing. . Proc Natl Acad Sci U S A 107:, 11513–11518. [CrossRef] [PubMed]
    [Google Scholar]
  24. Yusim K. , Dilan R. , Borducchi E. , Stanley K. , Giorgi E. , Fischer W. , Theiler J. , Marcotrigiano J. , Korber B. , Barouch D. H. . ( 2013; ). Hepatitis C genotype 1 mosaic vaccines are immunogenic in mice and induce stronger T-cell responses than natural strains. . Clin Vaccine Immunol 20:, 302–305. [CrossRef] [PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.057299-0
Loading
/content/journal/jgv/10.1099/vir.0.057299-0
Loading

Data & Media loading...

Supplements

Supplementary material 

PDF

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error